journal
MENU ▼
Read by QxMD icon Read
search

Pharmacogenomics

journal
https://www.readbyqxmd.com/read/29701129/feasibility-and-implementation-of-cyp2c19-genotyping-in-patients-using-antiplatelet-therapy
#1
Thomas O Bergmeijer, Gerrit Ja Vos, Daniël Mf Claassens, Paul Wa Janssen, Remko Harms, Richard van der Heide, Folkert W Asselbergs, Jurriën M Ten Berg, Vera Hm Deneer
AIM: A tailored antiplatelet strategy based on CYP2C19 genotype may reduce atherothrombotic and bleeding events. We describe our experience with CYP2C19 genotyping, using on-site TaqMan or Spartan genotyping or shipment to a central laboratory. METHODOLOGY: Data from two ongoing projects were used: Popular Risk Score project (non-urgent percutaneous coronary intervention patients) and the Popular Genetics study (ST-segment elevation myocardial infarction patients)...
April 27, 2018: Pharmacogenomics
https://www.readbyqxmd.com/read/29701127/slc04a1-slc22a2-and-slc28a2-variants-not-related-to-methotrexate-efficacy-or-toxicity-in-rheumatoid-arthritis-patients
#2
Frank Eektimmerman, Jesse J Swen, Stefan Böhringer, Stella Aslibekyan, Cornelia F Allaart, Henk-Jan Guchelaar
AIM: A third of rheumatoid arthritis patients discontinue methotrexate treatment due to inefficacy or toxic side effects. Recently, an association between SLC04A1 rs2236553, SLC22A2 rs624249 and rs316019, and SLC28A2 rs10519020 and rs1060896 with the efficacy and toxicity of methotrexate was reported. This study aims to replicate these findings in an independent cohort (n = 324). METHODS:  Regression analyses tested the associations between genotype and methotrexate response or toxicity...
April 27, 2018: Pharmacogenomics
https://www.readbyqxmd.com/read/29701126/-what-do-we-know-about-tacrolimus-pharmacogenetics-in-transplant-recipients
#3
Dirk Rj Kuypers
No abstract text is available yet for this article.
April 27, 2018: Pharmacogenomics
https://www.readbyqxmd.com/read/29701121/what-do-we-need-to-transfer-pharmacogenetics-findings-into-the-clinic
#4
Elise Ma Slob, Susanne Jh Vijverberg, Mariëlle W Pijnenburg, Gerard H Koppelman, Anke-Hilse Maitland-van der Zee
No abstract text is available yet for this article.
April 27, 2018: Pharmacogenomics
https://www.readbyqxmd.com/read/29701105/a-prospective-study-of-the-impact-of-agtr1-a1166c-on-the-effects-of-candesartan-in-patients-with-heart-failure
#5
Simon de Denus, Marie-Pierre Dubé, René Fouodjio, Thao Huynh, Marie-Hélène LeBlanc, Serge Lepage, Richard Sheppard, Nadia Giannetti, Joël Lavoie, Asmaa Mansour, Sylvie Provost, Valérie Normand, Ian Mongrain, Mathieu Langlois, Eileen O'Meara, Anique Ducharme, Normand Racine, Marie-Claude Guertin, Jacques Turgeon, Michael S Phillips, Jean-Lucien Rouleau, Jean-Claude Tardif, Michel White
AIM: To evaluate the impact of AGTR1 A1166C (rs5186) on the response to candesartan in patients with heart failure. MATERIALS & METHODS: Prospective, multicentre, open-label study. We studied 299 symptomatic patients with heart failure presenting a left ventricular ejection fraction ≤40%. RESULTS: Reductions in the primary end points of natriuretic peptides were not significantly associated with AGTR1 A1166C. Nevertheless, carrying the 1166C allele was associated with a greater compensatory increase in renin activity (p = 0...
April 27, 2018: Pharmacogenomics
https://www.readbyqxmd.com/read/29701078/genotype-guided-warfarin-therapy-current-status
#6
Letícia C Tavares, Leiliane R Marcatto, Paulo Cjl Santos
Warfarin pharmacogenomics has been an extensively studied field in the last decades as it is focused on personalized therapy to overcome the wide interpatient warfarin response variability and decrease the risk of side effects. In this expert review, besides briefly summarizing the current knowledge about warfarin pharmacogenetics, we also present an overview of recent studies that aimed to assess the efficacy, safety and economic issues related to genotype-based dosing algorithms used to guide warfarin therapy, including randomized and controlled clinical trials, meta-analyses and cost-effectiveness studies...
April 27, 2018: Pharmacogenomics
https://www.readbyqxmd.com/read/29637802/corrigendum
#7
(no author information available yet)
No abstract text is available yet for this article.
April 11, 2018: Pharmacogenomics
https://www.readbyqxmd.com/read/29629838/a-genetic-polymorphism-in-the-cyp1b1-gene-in-patients-with-squamous-cell-carcinoma-of-the-esophagus-an-iranian-mashhad-cohort-study-recruited-over-10-years
#8
Azam Rastgar Moghadam, Mehrane Mehramiz, Malihe Entezari, Hamideh Aboutalebi, Fatemeh Kohansal, Parisa Dadjoo, Hamid Fiuji, Mohammadreza Nasiri, Seyed Amir Aledavood, Kazem Anvari, Saeideh Ahmadi Simab, Mohammad Sadegh Khorrami, Ali Moradi, Seyed Mahdi Hassanian, Gordon A Ferns, Soodabeh Shahid Sales, Amir Avan
AIM: Esophageal cancer is the eighth most common cancer globally and the seventh most common cause of cancer-related deaths in men. Recent studies have shown that CYP450, family 1, subfamily B, polypeptide 1, which plays a role in the metabolism of xenobiotics, is associated with several cancers. Therefore, in the present study we investigated the association between a genetic variant, CYP1B1-rs1056836 gene, with the clinical characteristics of patients with squamous cell carcinoma of the esophagus (ESCC)...
April 9, 2018: Pharmacogenomics
https://www.readbyqxmd.com/read/29629825/cyp3a-pharmacogenetic-association-with-tacrolimus-pharmacokinetics-differs-based-on-route-of-drug-administration
#9
Amy L Pasternak, Lu Zhang, Daniel L Hertz
Tacrolimus is prescribed to the majority of transplant recipients to prevent graft rejection, and although patients are maintained on oral administration, nonoral routes of administration are frequently used in the initial post-transplant period. CYP3A5 genotype is an established predictor of oral tacrolimus dose requirements, and clinical guideline recommendations exist for CYP3A5-guided dose selection. However, the association between CYP3A5 and nonoral tacrolimus administration is currently poorly understood, and differs from the oral tacrolimus relationship...
April 9, 2018: Pharmacogenomics
https://www.readbyqxmd.com/read/29629814/association-between-hla-b-15-02-and-oxcarbazepine-induced-cutaneous-adverse-reaction-a-meta-analysis
#10
Yiwei Liu, Yuncui Yu, Xiaolu Nie, Libo Zhao, Xiaoling Wang
AIM: HLA-B*15:02 has been demonstrated as a key risk factor for carbamazepine-induced severe cutaneous adverse reaction (sCAR), especially in Asian population. Oxcarbazepine (OXC) is a drug that has a similar structure of carbamazepine. However, the relationship between HLA-B*15:02 and induced cutaneous adverse reaction (cADR) remains unknown. This study aims to analyze this association in the published literature. METHOD: After filtering studies, eight studies were finally included for meta-analysis, including 32 sCAR cases, 112 mild cutaneous adverse reaction (mcADR) cases, 281 OXC tolerant control and 946 population control cases...
April 9, 2018: Pharmacogenomics
https://www.readbyqxmd.com/read/29629612/the-9p21-locus-as-a-potential-therapeutic-target-and-prognostic-marker-in-colorectal-cancer
#11
Afsane Bahrami, Seyed Mahdi Hassanian, Majid Khazaei, Masoumeh Gharib, Mahsa Rahmani, Hamid Fiuji, Mir Hadi Jazayeri, Mehrdad Moetamani-Ahmadi, Gordon A Ferns, Amir Avan
Colorectal cancer (CRC) is a major cause of cancer-related-death worldwide. Despite extensive efforts to identify valid biomarkers for the risk stratification of CRC patients, there are few of proven clinical utility. It is recognized that genetic factors play a major role in determining susceptibility to CRC. Recent genome-wide association studies have demonstrated common genetic variants in a region on chromosome 9p21 associated with an increased risk of CRC. Several genetic polymorphisms have been identified in this region that are associated with CRC...
April 9, 2018: Pharmacogenomics
https://www.readbyqxmd.com/read/29620434/transient-receptor-potential-polymorphism-and-haplotype-associate-with-crisis-pain-in-sickle-cell-disease
#12
Ellie H Jhun, Xiaoyu Hu, Nilanjana Sadhu, Yingwei Yao, Ying He, Diana J Wilkie, Robert E Molokie, Zaijie J Wang
AIM: Episodes of acute pain crisis contribute to considerable morbidity and mortality in sickle cell disease (SCD). Incomprehensive understanding of the underlying pain heterogeneity results in inadequate pain management. The transient receptor potential (TRP) family of voltage-gated ion channels acts as sensory transducers of diverse noxious stimuli. We performed an association study of polymorphisms in candidate genes TRPV1 and TRPA1 with pain in SCD patients. METHODS: Utilization rate, in other words, number of emergency department/acute care center admissions over 12 months as a result of pain crisis, served as a marker for acute pain...
April 5, 2018: Pharmacogenomics
https://www.readbyqxmd.com/read/29589488/associations-between-gene-polymorphisms-and-treatment-outcomes-of-methotrexate-in-patients-with-juvenile-idiopathic-arthritis
#13
Yuehong Chen, Kun Zou, Jianhong Sun, Yuan Yang, Gang Liu
AIM: Performance of a meta-analysis with respect to the genetic predictors of methotrexate (MTX) treatment outcomes, efficacy and toxicity, in patients with juvenile idiopathic arthritis (JIA). METHODS: Databases of OVID MEDLINE and OVID EMBASE were searched to collect the studies addressing correlations between gene polymorphisms and efficacy and/or toxicity in MTX-treated JIA patients. Pooled odds ratios (ORs) with 95% CIs were estimated in allelic, recessive and/or dominant models...
March 28, 2018: Pharmacogenomics
https://www.readbyqxmd.com/read/29580198/pharmacogenetics-of-oral-antidiabetic-therapy
#14
Anna-Maria Ordelheide, Martin Hrabě de Angelis, Hans-Ulrich Häring, Harald Staiger
Type 2 diabetes prevalence is still on the rise worldwide. Antidiabetic drugs are widely prescribed to patients with Type 2 diabetes. Most patients start with metformin which is mostly well tolerated. However, a high percentage of patients fail to achieve glycemic control. The effectiveness of metformin as well as most other antidiabetic drugs depends among other factors on interindividual genetic differences that are up to now ignored in the treatment of Type 2 diabetes. Interestingly, many genes influencing the effectiveness of antidiabetic drugs are Type 2 diabetes risk genes making matters worse...
March 27, 2018: Pharmacogenomics
https://www.readbyqxmd.com/read/29580174/effect-of-hydrochlorothiazide-on-serum-uric-acid-concentration-a-genome-wide-association-study
#15
Eero M Ala-Mutka, Jenni M Rimpelä, Frej Fyhrquist, Kimmo K Kontula, Timo P Hiltunen
AIM: To recognize genetic associations of hydrochlorothiazide-induced change in serum uric acid (SUA) concentration. PATIENTS & METHODS: We conducted a genome-wide association study on hydrochlorothiazide-induced change in SUA in 214 Finnish men from the GENRES study. Replication analyses were performed in 465 Finns from the LIFE study. RESULTS: In GENRES, we identified 31 loci associated with hydrochlorothiazide-induced change in SUA at p < 5 × 10-5 ...
March 27, 2018: Pharmacogenomics
https://www.readbyqxmd.com/read/29580163/from-homer-and-hippocrates-to-modern-personalized-medicine-is-there-a-role-for-pharmacoepigenomics-in-the-treatment-of-alcohol-addiction
#16
Georgia Ragia, Vangelis G Manolopoulos
From the earliest times to the present, alcohol has evolved as part of life and culture. For most adults, moderate alcohol use is harmless, however, it lies at one end of a range that moves through alcohol abuse to alcohol addiction. Alcohol addiction is a serious and chronic psychiatric disorder that, on top of its heavy consequences on health, also brings significant social and economic losses to individuals and society at large. Pharmacotherapy of alcohol addiction exists, but its effectiveness varies significantly among individuals...
March 27, 2018: Pharmacogenomics
https://www.readbyqxmd.com/read/29577811/are-haplotypes-in-a-single-methotrexate-pathway-more-predictive-for-response-in-rheumatoid-arthritis-than-in-different-pathways
#17
Tomas Soukup, Ivan Barvik, Jana Nekvindova, Tomas Veleta, Ales A Kubena, Jurjen Duintjer Tebbens, Petr Pavek, Martin Dosedel
Letter to the editor with respect to: Lima A, Bernardes M, Azevedo R, Seabra V and Medeiros R. Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome. Pharmacogenomics 17(15), 1649-1674 (2016).
March 26, 2018: Pharmacogenomics
https://www.readbyqxmd.com/read/29577807/changing-vision-a-review-of-pharmacogenetic-studies-for-treatment-response-in-age-related-macular-degeneration-patients
#18
Janan Arslan, Paul N Baird
Nonresponsiveness to age-related macular degeneration (AMD) treatments has become a growing concern in ophthalmology. Disparity among publications that have assessed pharmacogenetic (PGx) connections between AMD disease genes and treatments has delayed the implementation of PGx testing in AMD. We assessed all AMD PGx publications to identify the degree of agreement for publications within similar ethnic cohorts and worldwide, and the causes for differences in study outcomes. There are no accepted genotype-phenotype correlations, either within similar ethnic cohorts or worldwide...
March 26, 2018: Pharmacogenomics
https://www.readbyqxmd.com/read/29569526/pharmacogenetics-and-the-treatment-of-chronic-myeloid-leukemia-how-relevant-clinically-an-update
#19
Ravindran Ankathil, Husin Azlan, Abu Abdullah Dzarr, Abdul Aziz Baba
Despite the excellent efficacy and improved clinical responses obtained with imatinib mesylate (IM), development of resistance in a significant proportion of chronic myeloid leukemia (CML) patients on IM therapy have emerged as a challenging problem in clinical practice. Resistance to imatinib can be due to heterogeneous array of factors involving BCR/ABL-dependent and BCR/ABL-independent pathways. Although BCR/ABL mutation is the major contributory factor for IM resistance, reduced bio-availability of IM in leukemic cells is also an important pharmacokinetic factor that contributes to development of resistance to IM in CML patients...
March 23, 2018: Pharmacogenomics
https://www.readbyqxmd.com/read/29706123/pharmacogenomics-of-blood-lipid-regulation
#20
Marc-André Legault, Jean-Claude Tardif, Marie-Pierre Dubé
Blood lipids are important modifiable risk factors for coronary heart disease and various drugs have been developed to target lipid fractions. Considerable efforts have been made to identify genetic variants that modulate responses to drugs in the hope of optimizing their use. Pharmacogenomics and new biotechnologies now allow for meaningful integration of human genetic findings and therapeutic development for increased efficiency and precision of lipid-lowering drugs. Polygenic predictors of disease risk are also changing how patient populations can be stratified, enabling targeted therapeutic interventions to patients more likely to derive the highest benefit, marking a shift from single variant to genomic approaches in pharmacogenomics...
May 2018: Pharmacogenomics
journal
journal
34814
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"